Mild primary hyperparathyroidism: A literature review

Oncologist

Volumn 19, Issue 9, 2014, Pages 919--929

  Applewhite, Megan K ^a   Schneider, David F ^b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Hypercalcemia; Hyperparathyroidism; Nephrolithiasis; Parathyroid hormone; Parathyroidectomy; Primary hyperparathyroidism

Indexed keywords

ALENDRONIC ACID; CALCIUM ION; CINACALCET; PARATHYROID HORMONE; RALOXIFENE; VITAMIN D; CALCIUM;

ARTICLE; BONE DENSITY; BONE DISEASE; CALCIUM INTAKE; DISEASE COURSE; HUMAN; HYPERCALCEMIA; INCIDENCE; MENTAL HEALTH; OSTEOPENIA; OSTEOPOROSIS; PARATHYROIDECTOMY; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SYMPTOM; TREATMENT OUTCOME; BLOOD; COMPLICATION; HYPERPARATHYROIDISM, PRIMARY; NEPHROLITHIASIS; PATHOLOGY; UNITED STATES;

BONE DENSITY; CALCIUM; HUMANS; HYPERPARATHYROIDISM, PRIMARY; NEPHROLITHIASIS; PARATHYROID HORMONE; PARATHYROIDECTOMY; UNITED STATES;

EID: 84906970501     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0084     Document Type: Article

References (83)

1. Adler JT, Sippel RS, Chen H. New trends in parathyroid surgery. Curr Probl Surg 2010;47: 958-1017.
2. Heath H III, Hodgson SF, Kennedy MA. Primary hyperparathyroidism: Incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980;302:189-193.
3. Lundgren E, Hagström EG, Lundin J et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg 2002;26:931-936.
4. Yeh MW, Ituarte PH, Zhou HC et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013;98:1122-1129.
5. Wermers RA, Khosla S, Atkinson EJ et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: An update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:171-177.
6. Lo CY, Chan WF, Kung AW et al. Surgical treatment for primary hyperparathyroidism in Hong Kong: Changes in clinical pattern over 3 decades. Arch Surg 2004;139:77-82.
7. Abood A, Vestergaard P. Increasing incidence of primary hyperparathyroidism in Denmark. Dan Med J 2013;60:A4567.
8. Zhao L, Liu JM, He XY et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: Data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab 2013;98:721-728.
9. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathyroidism: A "forme fruste" of an old disease. J Clin Endocrinol Metab 2003;88:5348-5352.
10. Bilezikian JP, Potts JT Jr., Fuleihan G-H et al. Summary statement from a workshop on asymp-tomatic primary hyperparathyroidism: A perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353-5361.
11. Lowe H, McMahon DJ, Rubin MR et al. Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92:3001-3005.
12. Eastell R, Arnold A, Brandi ML et al. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:340-350.
13. Chen H. Primary hyperparathyroidism. In: Cameron JL, Cameron AM, eds. Current Surgical Therapy. Philadelphia, PA: Elsevier Saunders, 2011.
14. Amaral LM, Queiroz DC, Marques TF et al. Normocalcemic versus hypercalcemic primary hyperparathyroidism: More stone than bone? J Osteoporos 2012;2012:128352.
15. Talpos GB, Bone HG III, Kleerekoper M et al. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: Patient description and effects on the SF-36 health survey. Surgery 2000;128:1013-1020; discussion 1020-1021.
16. Burney RE, Jones KR, Christy B et al. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery 1999; 125:608-614.
17. Zhao L, Zhang MJ, Zhao HY et al. PTH inhibition rate is useful in the detection of early-stage primary hyperparathyroidism. Clin Biochem 2011;44:844-848.
18. Rao DS, Phillips ER, Divine GW et al. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004; 89:5415-5422.
19. Wallace LB, Parikh RT, Ross LV et al. The phenotype of primary hyperparathyroidism with normal parathyroid hormone levels: How low can parathyroid hormone go? Surgery 2011;150:1102-1112.
20. Carneiro-Pla DM, Irvin GL III, Chen H. Consequences of parathyroidectomy in patients with "mild" sporadic primary hyperparathyroidism. Surgery 2007;142:795-799.
21. Maruani G, Hertig A, Paillard M et al. Normocalcemic primary hyperparathyroidism: Evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003;88: 4641-4648.
22. Wade TJ, Yen TW, Amin AL et al. Surgical management of normocalcemic primary hyperpara-thyroidism. World J Surg 2012;36:761-766.
23. Lundgren E, Ridefelt P, Akerström G et al. Parathyroid tissue in normocalcemic and hypercalcemic primary hyperparathyroidism recruited by health screening. World J Surg 1996;20:727-735.
24. Lundgren E, Rastad J, Thrufjell E et al. Population-based screening for primary hyperpara-thyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287-294.
25. Alhefdhi A, Pinchot SN, Davis R et al. The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range. World J Surg 2011;35:2006-2009.
26. Schneider DF, Burke JF, Ojomo KA et al. Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism. Ann Surg Oncol 2013;20:4205-4211.
27. NIH conference. NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus development conference statement. Ann Intern Med 1991;114:593-597.
28. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335-339.
29. Hollenberg AN, Arnold A. Hypercalcemia with low-normal serum intact PTH: A novel presentation of primary hyperparathyroidism. Am J Med 1991;91: 547-548.
30. Rao DS, Wilson RJ, Kleerekoper M et al. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: Evidence for biphasic disease course. J Clin Endocrinol Metab 1988;67:1294-1298.
31. Cusano NE, Silverberg SJ, Bilezikian JP. Normo-calcemic primary hyperparathyroidism. J Clin Densitom 2013;16:33-39.
32. Silverberg SJ, Shane E, Jacobs TP et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999;341:1249-1255.
33. Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2010;54:106-109.
34. Tordjman KM, Greenman Y, Osher E et al. Characterization of normocalcemic primary hyperparathyroidism. Am J Med 2004;117:861-863.
35. Marques TF, Vasconcelos R, Diniz E et al. Normocalcemic primary hyperparathyroidism in clinical practice: An indolent condition or a silent threat? Arq Bras Endocrinol Metabol 2011;55: 314-317.
36. Adler JT, Sippel RS, Schaefer S et al. Surgery improves quality of life in patients with "mild" hyperparathyroidism. Am J Surg 2009;197:284-290.
37. Bergenfelz A, Lindblom P, Lindergård B et al. Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism. World J Surg 2003;27:481-485.
38. Amin AL, Wang TS, Wade TJ et al. Normal PTH levels in primary hyperparathyroidism: Still the same disease? Ann Surg Oncol 2011;18:3437-3442.
39. Siperstein AE, Shen W, Chan AK et al. Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery. Arch Surg 1992;127:1157-1163.
40. Bilezikian JP, Silverberg SJ. Clinical practice: Asymptomatic primary hyperparathyroidism. N Engl J Med 2004;350:1746-1751.
41. Monchik JM, Lamberton RP, Roth U. Role of the oral calcium-loading test with measurement of intact parathyroid hormone in the diagnosis of symptomatic subtle primary hyperparathyroidism. Surgery 1992;112:1103-1110.
42. Silverberg SJ. Natural history of primary hyperparathyroidism. Endocrinol Metab Clin North Am 2000;29:451-464.
43. Invernizzi M, Carda S, Righini V et al. Different PTH response to oral peptone load and oral calcium load in patients with normocalcemic primary hyperparathyroidism, primary hyperparathyroidism, and healthy subjects. Eur J Endocrinol 2012; 167:491-497.
44. Mischis-Troussard C, Goudet P, Verges B et al. Primary hyperparathyroidism with normal serum intact parathyroid hormone levels. QJM 2000;93: 365-367.
45. Farford B, Presutti RJ, Moraghan TJ. Nonsurgical management of primary hyperparathyroidism. Mayo Clin Proc 2007;82:351-355.
46. Silverberg SJ, Bilezikian JP, Bone HG et al. Therapeutic controversies in primary hyperparathyroidism. J Clin Endocrinol Metab 1999;84:2275-2285.
47. Russell RG. Bisphosphonates: From bench to bedside. Ann N Y Acad Sci 2006;1068:367-401.
48. Parker CR, Blackwell PJ, Fairbairn KJ et al. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: A 2-year study. J Clin Endocrinol Metab 2002;87:4482-4489.
49. Chow CC, Chan WB, Li JK etal. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:581-587.
50. Khan AA, Bilezikian JP, Kung AW et al. Alendr-onate in primary hyperparathyroidism: A doubleblind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:3319-3325.
51. Shoback DM, Bilezikian JP, Turner SA et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-5649.
52. Marcocci C, Cetani F. Update on the use of cinacalcet in the management of primary hyperparathyroidism. J Endocrinol Invest 2012;35:90-95.
53. Rubin MR, Lee KH, McMahon DJ et al. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:1174-1178.
54. Muchmore DB. Raloxifene: A selective estro-genreceptormodulator (SERM) withmultipletarget system effects. The Oncologist 2000;5:388-392.
55. AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract 2005;11:49-54.
56. Udelsman R, Pasieka JL, Sturgeon C et al. Surgery for asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:366-372.
57. Stavrakis AI, Ituarte PH, Ko CY et al. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery 2007;142: 887-899; discussion 887-899.
58. Sosa JA, Bowman HM, Tielsch JM et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320-330.
59. Chen H, Mack E, Starling JR. A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: Which is most reliable? Ann Surg 2005;242:375-380; discussion 380-383.
60. Libutti SK, Alexander HR, Bartlett DL et al. Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. Surgery 1999;126:1145-1151.
61. Irvin GL III, Dembrow VD, Prudhomme DL. Operative monitoring of parathyroid gland hyperfunction. Am J Surg 1991;162:299-302.
62. Carneiro DM, Solorzano CC, Nader MC et al. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: Which criterion is the most accurate? Surgery 2003;134: 973-981.
63. Chiu B, Sturgeon C, Angelos P. Which intraoperative parathyroid hormone assay criterion best predicts operative success? A study of 352 consecutive patients. Arch Surg 2006;141:483-488.
64. Gordon LL, Snyder WH III, Wians F Jr. et al. The validity of quick intraoperative parathyroid hormone assay: An evaluation in seventy-two patients based on gross morphologic criteria. Surgery 1999; 126:1030-1035.
65. Irvin GL III, Molinari AS, Figueroa C et al. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999;229:874-879.
66. Yang GP, Levine S, Weigel RJ. A spike in parathyroid hormone during neck exploration may cause a false-negative intraoperative assay result. Arch Surg 2001;136:945-949.
67. Irvin GL III, Deriso GT III. A new, practical intraoperative parathyroid hormone assay. Am J Surg 1994;168:466-468.
68. Weber CJ, Ritchie JC. Retrospective analysis of sequential changes in serum intact parathyroid hormone levels during conventional parathyroid exploration. Surgery 1999;126:1139-1143; discussion 1143-1144.
69. Bilezikian JP, Rubin M, Silverberg SJ. Asymptomatic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2006;50:647-656.
70. Ambrogini E, Cetani F, Cianferotti L et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: A prospective, randomized clinical trial. J Clin Endocrinol Metab 2007; 92:3114-3121.
71. Bollerslev J, Jansson S, Mollerup CL et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: A prospective, randomized trial. J Clin Endocrinol Metab 2007;92:1687-1692.
72. Smith JC, Page MD, John R et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000;85: 3515-3519.
73. Ringe JD. Reversible hypertension in primary hyperparathyroidism: Pre- and posteroperative blood pressure in 75 cases. Klin Wochenschr 1984; 62:465-469.
74. Dominiczak AF, Lyall F, Morton JJ et al. Blood pressure, left ventricular mass and intracellular calcium in primary hyperparathyroidism. Clin Sci (Lond) 1990;78:127-132.
75. Nilsson IL, Aberg J, Rastad J et al. Circadian cardiac autonomic nerve dysfunction in primary hyperparathyroidism improves after parathyroidectomy. Surgery 2003;134:1013-1019.
76. Almqvist EG, Bondeson AG, Bondeson L et al. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002;132:1126-1132.
77. Hagström E, Lundgren E, Lithell H et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: Population based study over five years. Clin Endocrinol (Oxf) 2002;56:253-260.
78. Almqvist EG, Becker C, Bondeson AG et al. Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: A prospective and randomized study. Surgery 2004; 136:1281-1288.
79. Monchik JM, Gorgun E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery 2004;136:1242-1246.
80. Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006;140:874-881; discussion 881-882.
81. Sejean K, Calmus S, Durand-Zaleski I et al. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: A decision analysis. Eur J Endocrinol 2005;153: 915-927.
82. Oltmann SC, Maalouf NM, Holt S. Significance of elevated parathyroid hormone after parathyroidectomy for primary hyperparathyroidism. Endocr Pract 2011;17(Suppl 1):57-62.
83. Ning L, Sippel R, Schaefer S et al. What is the clinical significance of an elevated parathyroid hormone level after curative surgery for primary hyperparathyroidism? Ann Surg 2009;249:469-472.